secwatch.observer — SEC 8-K summary
======================================

Issuer:     Keros Therapeutics, Inc. (KROS)
CIK:        0001664710
Form:       8-K
Filed at:   2026-09-08T20:02:45+00:00
Accession:  0001664710-26-000053
Event type: other_material
Sentiment:  positive
Materiality: 0.45
Item codes: 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Keros authorizes $5M buyback after $20M Takeda milestone for elritercept; cash runway to 2H 2028
--------------------------------------------------------------------------------

- Board approved $5 million share repurchase program of KROS common stock, announced September 8, 2026.
- Program follows $20 million development milestone from Takeda Pharmaceuticals triggered by first patient dose in ELRiSE MDS trial of elritercept.
- Repurchases may occur in open market or other means; timing depends on market price and conditions; may be suspended or discontinued.
- Cash and equivalents were $257.6 million as of June 30, 2026; funding runway extended into second half of 2028 after milestone and buyback.
- Milestone confirms elritercept MDS development progress under license agreement with Takeda.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/0001664710-26-000053-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1664710/000166471026000053/kros-20260908.htm
  HTML page:      https://secwatch.observer/filing/0001664710-26-000053

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer